

Progenics Cord Blood Cryobank Annual Quality Report



QA.006-3-EXT V1.3 Effective Date: 2022-04-05

Company Profile

Progenics Cord Blood Cryobank is a leader in delivering consistent, high quality cord blood processing results, with over 18 years of experience in the cord blood banking industry. Progenics is AABB and FACT Accredited and is registered with both Health Canada and the Food and Drug Administration (FDA) in the United States. The company's mission is to provide the highest quality processing and long-term safe, secure storage of cord blood stem cells, to ensure their availability when needed.

Progenics Cord Blood Cryobank's *modified double stem cell extraction processing technique*, developed by the company's Research and Development Team, ensures that we can guarantee every processed cord blood sample will yield the highest possible number of Total Nucleated Cells (TNC).

Contact Us:

Toll Free: 1-866-921-1666

Phone: 416-221-1666

Email: info@progenics.ca

Address: 701 Sheppard Avenue East
Suite 310,
Toronto, ON- M2K 2Z3
Canada

Website: www.progenics.ca

Report Summary

This quality report summarizes the processing results from all the cord blood samples processed by Progenics Cord Blood Cryobank from 2021. The quality indicators referenced in this report present 5 key variables: The Yield (%) of Total Nucleated Cells (TNC), Total Viable Nucleated Cells (TVNC), CD34+ Viability, Total Nucleated Cell Count, and Viable CD34+ Cell Count.

This report also compares the average monthly and annual percentage yields of TNC including stem cells, the average percentage of total viable nucleated cells, and the average percentage of viable CD34+ cells.

Progenics uses a *modified double stem cell extraction processing technique* which ensures that a higher number of viable nucleated cells are banked for potential medical need. Based on this technique, the average recovery rate for TNCs banked has been 95.61% which is significantly greater than the industry and shows our dedication to maintaining the highest quality standards for each client.

From 2006, 2008 and 2010 a selection of Cord Blood Units have been tested as part of the Progenics Stability Program to ensure ongoing acceptability of current parameters following cryopreservation. These tests have revealed that the average TNC Viability (%) is 78.96% and the CD34+ Viability (%) is 95.04%.

2021 Monthly Report


Month	Total Nucleated Cells (TNC) Yield (%)	Total Nucleated Cell Viability (%)	CD34+ Viability (%)	Total Nucleated Cell Count (x10 ⁶ /unit)	Viable CD34+ Cell Count (x10 ⁶ /unit)
January	95.97	94.27	98.83	607.12	1.94
February	97.50	99.14	90.85	810.88	2.66
March	97.06	98.94	92.85	860.67	98.94
April	95.92	95.66	99.45	826.03	3.02
May	95.40	92.24	98.63	834.95	2.83
June	95.09	92.93	98.66	924.10	3.12
July	95.44	94.07	98.49	699.31	2.30
August	95.35	94.70	98.66	787.76	2.73
September	94.39	94.00	99.10	827.79	2.71
October	94.80	92.37	98.40	812.31	2.43
November	95.16	85.00	95.73	804.42	3.46
December	95.21	90.83	96.91	874.20	4.36
Annual average	95.61	92.48	98.41	805.8	2.88

Notes:

TNC TNC includes all nucleated cells such as stem cells and nucleated red blood cells.

CD34+ Cells Hematopoietic Progenitor Cells

Viability Cell viability is the percentage of viable cells in a processed cord blood sample. The viability of cells is evaluated by either measurement of cell membrane integrity or by measuring certain functions of the cells from a total cell sample.



Conclusion: Comparing Annual Averages

Based on the above data, we confidently report that for 2021, the annual averages are determined for the following parameters:

Parameter	Annual Average
Total Nucleated Cell Yield	95.61%
Total Nucleated Cell Viability	92.48%
Viable CD34+ Cells	98.41%
Total Nucleated Cell Count	805.8x10 ⁶ /unit
Viable CD34+ Cell Count	2.88x10 ⁶ /unit

The above results have been made possible due to our *modified double stem cell extraction processing technique* which surpasses our internal quality standards by over 10%.

Progenics quality policy assures that processed cord blood units (CBU) will contain the highest possible yield of total nucleated cells (TNC). Once a client’s CBU has been processed, and all processing parameters meet our cord blood bank acceptance criteria, the client will receive a *Certificate of Cryopreservation* which contains quality indicators of cord blood processing results.

After reviewing the data within this report, we can confidently claim that we offer our clients the highest consistent cord blood processing results.